UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): January 31, 2017
SERES THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| | | | |
Delaware | | 001-37465 | | 27-4326290 |
(State or other jurisdiction of incorporation or organization) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
200 Sidney Street
Cambridge, MA 02139
(Address of principal executive offices) (Zip Code)
(617)945-9626
(Registrant’s telephone number, include area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule14a-12 under the Exchange Act (17 CFR240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule14d-2(b) under the Exchange Act (17 CFR240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule13e-4(c) under the Exchange Act (17 CFR240.13e-4(c)) |
Item 7.01. | Regulation FD Disclosure. |
On January 31, 2017, Seres Therapeutics, Inc. (the “Company”) will host an investor conference call and live webcast to present the results of itsin-depth analyses of the previously reportedSER-109 Phase 2,8-week clinical study data in patients with multiply recurrentClostridium difficile infection. A copy of the slide presentation from this conference call is attached as Exhibit 99.1 to this Current Report on Form8-K. The slide presentation will be archived for approximately 30 days in the “Investors & Media” portion of the Company’s website atwww.serestherapeutics.com.
The information in Item 7.01 of this Current Report on Form8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.
Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
| | |
Exhibit No. | | Exhibit Description |
| |
99.1 | | SER-109 Phase 2 Study Analysis Slide Deck for Presentation on January 31, 2017 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | |
| | | | SERES THERAPEUTICS, INC. |
| | | |
Date: January 31, 2017 | | | | By: | | /s/ Eric D. Shaff |
| | | | Name: | | Eric D. Shaff |
| | | | Title: | | Executive Vice President and Chief Financial Officer |
EXHIBIT INDEX
| | |
Exhibit No. | | Exhibit Description |
| |
99.1 | | SER-109 Phase 2 Study Analysis Slide Deck for Presentation on January 31, 2017 |